Core One Labs files patent for protection of Biosynthetic NMT production
by CM Staff
The company says its production process can manufacture GMP compliant API grade NMT, and it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms.
VANCOUVER — Vocan Biotechnologies Inc., a subsidiary of Core One Labs Inc. has filed a patent application with the United States Patent and Trademark Office for the production of biosynthetic N-methyltryptamine through its recombinant production system.
N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor.
The patent entitled “Production of Psychedelic Compounds” protects Core One’s production system. The system, under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, is designed to make bacteria act as a biological factory and produce bio-identical psychedelic analogs such as biosynthetic N-methyltryptamine (NMT.)
The company says its production process can manufacture GMP compliant API grade NMT, and it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms.
“Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors. The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio,” stated Dr. Bob Hancock, CEO of Vocan Biotechnologies in a statement.
